Stock Market - List of large cap stocks that are up over 100% in the last 6 months. We like any of these to run further? |
- List of large cap stocks that are up over 100% in the last 6 months. We like any of these to run further?
- Elon Musk Sells Another $1B Worth Of Tesla Shares
- Ford is worth $40.00
- 【Pre-market Analysis】November 24th
- Meta Stock Price Falls 2% While Metaverse Cryptos Score Fresh Gains
- Manscaped to go public via $1 billion SPAC deal
- Stop Loss Triggered Under The Daily Low - Dark Pool Transaction
- Market open - Tuesday, November 23rd, 2021
- “Rounding Bottom” & “Golden Cross” - Extremely bullish $DM chart formation!
- Warren Buffett and Charlie Munger on when to sell a stock
- $GOEV - 2 Unfolding stories (or maybe 3) that will lift this American EV maker with 50% or more. Some SI implied!
- New weekly gainers - top 3 most hyped stocks on Twitter!
- S&P EOD Visual Summary: Nov 23
- QQQ vs TQQQ long term
- An Alternate View on the Oramed (ORMP) Short Report
- Nasdaq + X?
- Would it be better to leave my free funds into a slow but always increasing asset or to just leave it as is
- DD on $ETON
- Thoughts on PTRA? Or LEV? Electric bus manufacturers.
- Here's Your Daily Market Brief For November 23rd
- Fidelity mutual funds selection
- The Impeding Space Bubble
| Posted: 23 Nov 2021 03:44 PM PST
| ||
| Elon Musk Sells Another $1B Worth Of Tesla Shares Posted: 23 Nov 2021 10:27 PM PST | ||
| Posted: 24 Nov 2021 12:32 AM PST | ||
| 【Pre-market Analysis】November 24th Posted: 24 Nov 2021 03:27 AM PST The Dow saw ups and downs earlier Tuesday, and surged to a day high near the end of the trading, closing nearly 200 points higher. Tech stocks under pressure dragged the Nasdaq down 1.6% once, which narrowed significantly at the market close. Oil and gas stocks, and bank stocks climbed against the market trend, while pandemic stocks, takeout stocks and silver stocks led the decline. Battery stocks once strong saw quick declines in a continuous manner, panicking the market. However, the market depth is actually improving; industries with large business cycle such as bank, energy and basic materials are continuously climbing upon the end of adjustment. Due to differences in positions, people have quite different sensations towards the market. As the long weekend approaches, mid-to long-term investors would better have a rest. [link] [comments] | ||
| Meta Stock Price Falls 2% While Metaverse Cryptos Score Fresh Gains Posted: 24 Nov 2021 03:55 AM PST
| ||
| Manscaped to go public via $1 billion SPAC deal Posted: 23 Nov 2021 01:22 PM PST
| ||
| Stop Loss Triggered Under The Daily Low - Dark Pool Transaction Posted: 23 Nov 2021 10:31 PM PST
| ||
| Market open - Tuesday, November 23rd, 2021 Posted: 23 Nov 2021 06:34 AM PST
| ||
| “Rounding Bottom” & “Golden Cross” - Extremely bullish $DM chart formation! Posted: 24 Nov 2021 04:21 AM PST
| ||
| Warren Buffett and Charlie Munger on when to sell a stock Posted: 23 Nov 2021 06:22 PM PST
| ||
| Posted: 23 Nov 2021 11:12 AM PST Here is the silver line : The very first Lifestyle car expected in 2022 will cost some 35K, BUT if the BB bill will pass the Senate with EV incentives intact inside, a Canoo Lifestyle Car will only cost $25K and it will be built in US. Compete with that! IN short about Canoo (GOEV): $GOEV - Canoo EV maker has surprised (pleasantly this time) its investors with a much faster go to market date (middle 2022 instead of early 2023 and a smaller loss then expected. Old news anyway as there is a lot more coming for them. Going long on a stock everybody wants to ask 2 important questions: What can move $GOEV lower (so I don't loose my money) and obviously - what can make it fly? Let's start with the first one: What can move $GOEV lower? Here are couple things that proved painful for investors recently in similar stocks or even for GOEV earlier. DEspac shaming - has passed already with many de-spacs performing like in the good old days from 2020. Warrant and PIPE dilution - passed in June. Bonds yields and aversion for risk - passed at least for the time beeing. Bond tapering is in the back mirror and interest rates hike is not yet on the table. Inflation - this will not pass. It used to be an initial headwind for every EV, AV, innovation stock but my take is this: they've already spend big money to build their business. No with high inflation, every piece of equipment that hey have already bought, every square meter of concrete in their factory, etc. is already more valuable because of inflation. Their built/invested assets will only increase in value with big inflation in the next years. Any competitor will have to spend a lot more next year or in 2023 to catch up with them, because of inflation. Pretty good moat there! No that we are good to go, we can move to catalysts: What can move $GOEV Higher A number of high impact stories are trending in investor communities. Let's take them one by one:
BBB Bill or Social Spending Bill will provide 8K incentive for every EV bought in US in order to boost EV use to tackle climate change. That ca go up to 12.5K if they'll have 4k union workers. But, wait, not for every EV - but only for those produced in US. Even GM is making EVs but they make them in Mexico. Canoo has factories in US. Not sure about those union workers (that might also happen) but with in their production in 2022, they'll be fully eligible for 8K incentive for every car made. The very first Lifestyle car expected in 2022 will cost some 35K, BUT if the BB bill will pass the Senate with EV incentives intact inside, a Canoo Lifestyle Car will only cost 28K and it will be built in US. Compete with that! Even more $GOEV is already in line for some healthy incentives - 400M from the factories in Arkansas and Oklahoma.
I know, the subject has been up there for years now, but every time APPLE move further or Media is publishing some rumors about it, APPLE Car is moving the market. Short story - Apple is planning for years to create its own car full of gadgets that all IOS users love with one of the most powerful AI on board. Apple is holding tens of Billions and is looking for partners to manufacture this new car. What connects Canoo with Apple care? A similar design shared between Canoo and Apple Car that is user centered, leaves a lot of room to cool displays and is up for grab. Blomberg has some details about that here: Canoo has never made a secret from the fact that has active partnerships and is looking for new blue chip partners that would us its platform. The hole point in their business concept was to have platform that can be integrated by almost any use, by a variety of tech partners, but with distinct accent on user centered vehicle with AV/AI in mind. (rings any bells? Yes - that is Apple car) Why the design looks like has been created by the same mastermind? Because IT WAS! Here is the second connection: The same mastermind engineer Ulrich Kranz, co-founder of Canoo and former CEO is now the engineer working to develop Apple Car. With a back ground in top EV engineering at BMW (i3 and i5) and Faraday Future for a while, Kranz has joined Apple earlier this year. You might say that leaving Canoo for Apple is a bad sign - but Kranz has kept is co-founder status at Canoo and Apple has always confirmed that will work with out sourcing partners to develop the car. This is only the last records connecting them but the links go much deeper, even from the founding efforts of Canoo. One of the main investors in Canoo is the Chang family, the same family controlling TPK, the Taiwan based company that provides that nice Apple displays and has done so since Iphone1. And there is one more story that needs more documentation: Canoo - WALLMART partnership rumor - well this more of a rumor based on moving its headquarters and the opening of a new manufacturing facility in Bentonville, Arkansas (Home of Wallmart). I wouldn't bet my money on it if I wouldn't have had already for all the other reason to invest in $GOEV. It would not surprise me if indeed they work on a partnership but until we know more about it... we can only hope. UPDATE 1 - today surfaced the news that Canoo Inc (GOEV) Executive Chairman and CEO Tony Aquila Bought $230.3 million of Shares [GuruFocus] sending a pretty string bullish signal for the stock. UPDATE 2 - Yesterday ORTEX was data showing that Friday, there were 31M shorted float on $GOEV. So you'd think that yesterday spike was also because many short sellers closed positions, right? Today - ORTEX is showing that Monday (yesterday) when stock popped with some 15-20% UP, the short seller increased that number. Last data on GOEV shows 32.5 M, so some 32% of the float, while the stock has turned bullish. Just you know - I am long on $GOEV with $27K in common, 500 Dec. 17 call @$12.5. and even some 300 26 Nov. Call @$12.5 Have fun! [link] [comments] | ||
| New weekly gainers - top 3 most hyped stocks on Twitter! Posted: 23 Nov 2021 10:39 AM PST
| ||
| S&P EOD Visual Summary: Nov 23 Posted: 23 Nov 2021 01:17 PM PST
| ||
| Posted: 23 Nov 2021 11:44 AM PST Hi Could anyone please explain to a beginner investor (me) why long term investing in TQQQ is not better than QQQ since both are always going up? 10 years investment in TQQQ should return 3x the money QQQ returns!? As TQQQ does not liquidate all your money if it drops below certain point like leveraged crypto does for instance, what is the main risk? If it drops, just wait till goes back up!? QQQ goes down 10% in a month, TQQQ goes down 30%, than QQQ recovers and then puts another 20% extra in next 6 months and TQQQ recovers and puts 60% in the same amount of time, if that's corect I am happy to get all in this 😂 Any advice please? 😊 [link] [comments] | ||
| An Alternate View on the Oramed (ORMP) Short Report Posted: 23 Nov 2021 05:52 AM PST For biotech watchers out there, I think we can all agree that yesterday was a rough one for Oramed, which witnessed double-digit losses on both NASDAQ and TASE. The catalyst for this dramatic downturn appears to be a short report published by Parallax View (https://www.parallax.bio/p/ormp-oramed), a relatively unknown/low-profile research body for the broader biotech/biomed sector. Yesterday, they released a scathing short report on ORMP in what looks like a broadside against one of NASDAQ's most bullish biotech tickers that, as of late October, was +823% YTD (https://www.nasdaq.com/articles/oramed-pharmaceuticals-nasdaq%3Aormp-investors-will-be-pleased-with-their-enviable-823). I took a look at the Parallax report, and wanted to share some of my own thoughts/analysis on their due diligence and what this may mean for Oramed investors. The "thesis statement" of the short report is as follows: "We believe Oramed is grossly overvalued at its sub-$1B market cap due to its questionable science, dubious clinical trials, absent strategy, poor management, and many other red flags longstanding since 2008." I want to break this sweeping statement into bite-size pieces and present some alternative perspectives that can better contextualize this particular source. The first major point mentioned by Parallax View is that they call Oramed's scientific approach and clinical trials into serious question. While I won't get into a granular analysis of their ongoing trials etc, two facts make this assertion hard to square with reality. Over the course of 2021, Oramed has been chugging along with two concurrent Phase 3 clinical trials for their oral insulin pills in accordance with FDA protocol. Regular press releases have marked encouraging progress for the trials' enrollment, and so far things appear to be progressing smoothly. Literally this morning they just announced reaching 75% enrollment for one of these Phase 3 FDA-compliant trials (https://finance.yahoo.com/news/oramed-reaches-75-enrollment-phase-132500268.html),. Now, if Oramed oral insulin solution was based on sketchy science and dubious trials as Parallax claims, I find it challenging to understand how their ongoing Phase 3 trials have failed to receive censure from the FDA, which is internationally recognized as the gold standard for clinical trials. In a similar vein, back in July 2021 Miriam Kidron (chief scientific officer at Oramed) co-authored a study in "Diabetes, Obesity, and Metabolism", a respected peer-reviewed scientific journal (https://dom-pubs.onlinelibrary.wiley.com/doi/10.1111/dom.14499). The Parallax View report devotes significant attention to undermining the scientific basis of this study. I won't go head-to-head on the technical details, but again, back to the basics: a peer-reviewed journal is considered a legitimate source. A substack page opened in July 2021 whose archive contains all of 10 prior analyses to date is not. For those interested, here is the documentation of the July peer review (https://publons.com/publon/10.1111/dom.14499/). And for future refference, kiddos--this is what a credible source looks like. The final section of the Parallax View short report attacks a number of intertwined accusations such as Oramed's lack of corporate strategy, poor management, and unspecified other red flags. It reserves some particular acrimony for CEO Nadav Kidron for performing global media appearances which, during the COVID economy and as head of one of NASDAQ's most bullish biotech companies, is well pretty standard. Instead of parrying Parallax View's various arguments, I again urge readers to turn to numerous credible analyst assessments and reports that claim exactly the contrary (see from Aegis Capital: https://www.oramed.com/wp-content/uploads/2021/06/Aegis-Company-Note-June-2021.pdf, Alliance Global Partners: https://www.oramed.com/wp-content/uploads/2021/08/AGP-August-2021.pdf, Canaccord Genuity: https://www.oramed.com/wp-content/uploads/2021/08/Canaccord-Analyst-Report-08-24-2021.pdf) Judging by the market's reaction to the Parallax View report yesterday, it looks like the short report touched a raw nerve. According to Fintel, FINRA/Dark Pool short volume for ORMP was 639K yesterday, up from 100K the day prior. All of the relevant short interest data isn't yet posted on NASDAQ's official page, but I wager we'll see a serious uptick in short activity for yesterday, potentially today given how premarket trading is going. At the end of the day I do think that ORMP has been slated for a pullback from an otherwise tremendously bullish year. That said, Parallax View takes this to the extremes in attempting to undercut every aspect of the company, from its science to its strategy and management. While their analysis raises some important points, it draw's serious conclusions without properly contending with the wealth of prior research/analysis published on this company in recent months. I'm not a professional biologist or biotech engineer, but I put my faith in real sources like peer-reviewed journals and respected equity research rather than new substacks with no independently verifiable attribution. Will be watching closely today, but DYOR, check your sources, ask questions, and trade wisely. This ain't financial advice and I am most certainly not your financial advisor. [link] [comments] | ||
| Posted: 24 Nov 2021 01:57 AM PST Hi Does someone know a similar index or even fund that covers Europe and or Asia tech stocks? [link] [comments] | ||
| Posted: 23 Nov 2021 10:59 AM PST I have a couple of grand in my portfolio that's been doing nothing for like a year. I've only invested maybe £600 into actual stocks. I was wondering why don't I just put all/most of my funds into slow but rising stocks e.g. like Apple, Mcodonals etc and then when I ACC want to invest in something I can sell some of that stock (most likely at a Lil profit) and then invest into something that I think has potential to rise in the future. The Question is:
[link] [comments] | ||
| Posted: 23 Nov 2021 06:12 PM PST Check out this pharmaceutical play. It has been beaten down the past few weeks after receiving an FDA approval. Here are some bullish reasons to consider investing:
[link] [comments] | ||
| Thoughts on PTRA? Or LEV? Electric bus manufacturers. Posted: 23 Nov 2021 06:24 AM PST
| ||
| Here's Your Daily Market Brief For November 23rd Posted: 23 Nov 2021 05:44 AM PST 📰 Top News S&P Futures: -0.03%; DOW Futures: +0.04%; Nasdaq Futures: -0.16% US stock futures are mixed on Tuesday morning as investors further mulled the implications of Jerome Powell's renomination to lead the US Federal Reserve. Biden chooses Powell - U.S. President Joe Biden announced that he is renominating Jerome Powell for a second term as Federal Reserve Chair and will put Fed Governor Lael Brainard as Vice Chairman. The move comes after weeks of speculation that Brainard might get the Chair position. Note: In making the move, Biden praised Powell for his "decisive" leadership during the Covid-19 crisis. No US lockdown - The Biden administration has no plans to curb future Covid-19 surges with a nationwide lockdown. "We can curb the spread of the virus without having to, in any way, shut down the economy" White House coronavirus response coordinator Jeff Zients said at a briefing. Note: Zients' comments come as Austria enters its 4th nationwide lockdown and the Netherlands institute a partial lockdown amid a Covid-19 surge rampaging across Europe in recent weeks. Cali ports make supply chain progress - The nation's busiest port complex will delay imposing fines on carriers for lingering containers awaiting pickup, citing significant improvements in the supply chain. The executive directors of the ports of Los Angeles and Long Beach said that since last month's announcement of the new fee, the ports have seen a decline of 33% in aging cargo on the docks. Note: The development comes as the nation contends with a supply chain squeeze while American shoppers ramp up their purchasing for the holiday gift-giving season. 🎯 Price Target Updates Guggenheim downgrades eBay. EBAY downgraded from BUY to NEUTRAL - $80 (from $85) Mizuho Securities upgrades Micron Technologies. MU upgraded from NEUTRAL to BUY - $95 (from $75) CFRA upgrades Bank of America. BAC upgraded from HOLD to BUY - $51 📻 In Other News Russia squares off with Ukraine - Russia is amassing troops and military equipment near the border of Ukraine, stirring fears that it may move to launch an invasion. Note: The US shared concerns about the possibility of an invasion, as well as intelligence indicating that Russia is positioning forces for a possible multi-directional push into Ukraine. Samsung mulling chip plant location - Samsung Electronics said it had not made a final decision on the location of a new $17 billion chip plant in the United States, after the Wall Street Journal reported it would be Taylor, Texas. Note: The world's biggest memory chipmaker said it is also considering sites in Arizona and New York. The new plant is set to make advanced logic chips used to power mobile devices and autonomous vehicles. Spacey's "House of Cards" crumbles - Oscar-winning actor Kevin Spacey was ordered last year to pay nearly $31 million to the studio behind Netflix's "House of Cards" for breaching his contract by violating the company's sexual harassment policy. Note: Spacey and his production companies, M. Profitt Productions and Trigger Street Productions were ordered to pay $29.5 million in damages, $1.2 million in attorneys' fees, and $235,000 in additional costs to MRC, the studio behind the production. 📅 This Week's Key Economic Calendar Tuesday: Markit US Manufacturing PMI Wednesday: Initial Jobless Claims, GDP annualized quarter over quarter Thursday: No notable reports scheduled for release Friday: No notable reports scheduled for release 📔 Snippet of the Day Quote of the day: "The stock market is filled with individuals who know the price of everything, but the value of nothing" -Mellody Hobson. [link] [comments] | ||
| Fidelity mutual funds selection Posted: 23 Nov 2021 05:33 PM PST
| ||
| Posted: 23 Nov 2021 04:52 PM PST They say to buy the rumor and sell the news when it comes to the market. Well while rumors are circulating about the space bubble I guess they aren't doing a convincing job because the prices keep going down. Now's the peak time to buy into the private space Industry. The amount of private rocket launches has quite literally sky rocketed in the past two years. With notable companies like Blue Origin and Virgin Galactic completing their first manned test flights. Astra just got into orbit this past week as well. The price of these stocks jump shortly after the big event but then slowly drop after the excitement leaves. Soon these tests will be in production and publicly listed companies will be pulling a lot of money with years of research giving them an advantage to competition. [link] [comments] |
![[link]](https://i.redd.it/5np8w0lamf181.jpg){kind=link}
![[link]](https://i.redd.it/giypkx86wc181.png){kind=link}
![[link]](https://i.redd.it/fsa7qbnfdj181.jpg){kind=link}
![[link]](https://i.redd.it/xg00pem4we181.png){kind=link}
![[link]](https://i.redd.it/3ruiwjueuc181.jpg){kind=link}
| You are subscribed to email updates from r/StockMarket - Reddit's Front Page of the Stock Market. To stop receiving these emails, you may unsubscribe now. | Email delivery powered by Google |
| Google, 1600 Amphitheatre Parkway, Mountain View, CA 94043, United States | |
No comments:
Post a Comment